Active immunotherapy to treat human cancer is one of the most rapidly developing fields in oncology. The Immune Monitoring Core Laboratory was established as a resource for investigators needing to monitor immunotherapy trials. The IMCL occupies 700 sq ft lab space with two adjacent 100 sq ft cell culture rooms in the new Center for Immunology Research (CCIR) facility. Created as a state-of-the-art facility, the goal of the lab is to work closely with each investigator at all stages of the clinical trial process by planning both the types of immune monitoring assays and number of data points suitable for each particular clinical trial, processing specimens, performing assays, and providing help with data interpretation. The IMCL also allows researchers to use dedicated equipment not usually available in individual labs. As part of this commitment to offer the most recent technology in immune monitoring to all researchers, the IMCL teams with industry and academic collaborators to develop new assays, to validate immune assays and to set rigorous quality control standards. The techniques used by the IMCL for immune monitoring include 1) cytokine ELISPOT assays;2) 6-color FACS phenotyping assays using HLA class I and class II peptide tetramers/multimers;3) intracellular cytokine staining methods;4) advanced ELISA-based technology that measures multiple cytokines in a single sample or reaction (multiplex cytokine analysis);5) newer T-cell proliferation assays using CFSE labeling coupled to FACS;6) more sensitive non-radioactive methods to determine antigenspecific CTL activity using FACS. The IMCL plays a key role in clinical trial development. During the previous funding period, IMCL services were used by 10 investigators from 8 of the 19 CCSG programs. 90 % of users had peer-reviewed funding and accounted for 80.7 % of utilization. Future plans are focused on Increasing the IMCL participation in CCSG-related clinical studies, as well as developing new assays to improve the amount and quality of information that can be obtained from a clinical trial.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-35
Application #
8144425
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
35
Fiscal Year
2010
Total Cost
$109,573
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Bose, Prithviraj; Gotlib, Jason; Harrison, Claire N et al. (2018) SOHO State-of-the-Art Update and Next Questions: MPN. Clin Lymphoma Myeloma Leuk 18:1-12
Le, Phuong M; Andreeff, Michael; Battula, Venkata Lokesh (2018) Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis. Haematologica :
Huang, Shengjian; Jiang, Changying; Zhang, Hui et al. (2018) The CD20-specific engineered toxin antibody MT-3724 exhibits lethal effects against mantle cell lymphoma. Blood Cancer J 8:33
Hwang, Jessica P; Ahmed, Sairah; Ariza-Heredia, Ella J et al. (2018) Low Rate of Cervical Cancer Screening among Women with Hematologic Malignancies after Stem Cell Transplant. Biol Blood Marrow Transplant 24:1094-1098
He, Jing; Huo, Lei; Ma, Junsheng et al. (2018) Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications. Am J Clin Pathol 149:253-261
Schembre, Susan M; Liao, Yue; O'Connor, Sydney G et al. (2018) Mobile Ecological Momentary Diet Assessment Methods for Behavioral Research: Systematic Review. JMIR Mhealth Uhealth 6:e11170
Abbas, Hussein A; Bui, Ngoc Hoang Bao; Rajapakshe, Kimal et al. (2018) Distinct TP63 Isoform-Driven Transcriptional Signatures Predict Tumor Progression and Clinical Outcomes. Cancer Res 78:451-462
Zhu, Lele; Xie, Xiaoping; Zhang, Lingyun et al. (2018) TBK-binding protein 1 regulates IL-15-induced autophagy and NKT cell survival. Nat Commun 9:2812
Viswanathan, Chitra; Faria, Silvana; Devine, Catherine et al. (2018) [18F]-2-Fluoro-2-Deoxy-D-glucose-PET Assessment of Cervical Cancer. PET Clin 13:165-177
Debnam, James M; Chi, Tzehping L; Ketonen, Leena et al. (2018) Superiority of Multidetector Computed Tomography With 3-Dimensional Volume Rendering Over Plain Radiography in the Assessment of Spinal Surgical Instrumentation Complications in Patients With Cancer. J Comput Assist Tomogr :

Showing the most recent 10 out of 12418 publications